Consistent with the role of RR in DNA replication and repair, a high RRM1 expression is known to be associated with a poor response to the DNA-damaging platinum drugs and to the RRM1-targeting drug gemcitabine, and thus led to poor outcomes in these cancer patients (33–35). Here, RRM1 is linked to cancer.